- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02298608
Efficacy and Safety of IRE for RMs
The Efficacy and Safety of Irreversible Electroporation for the Ablation of Renal Masses: A Prospective, Human, In-Vivo Study.
Background:
Electroporation or electropermeabilisation is a novel technique with the potential to overcome the main disadvantages of thermal ablation. It utilizes electric pulses, traveling between two or more electrodes, to create 'nanopores' in the cell membrane. If the applied current reaches a certain threshold these 'nanopores' become permanent resulting in cell death. The use of electric current means that IRE is not susceptible to 'thermal sink' leading to consistent ablation results. IRE ablation targets the cell membrane, sparing tissue architecture and minimizing damage to blood vessels, nerves and the renal collecting system.
The first in human studies have proven the safety of IRE for the ablation of small renal masses. However the efficacy of IRE through histopathological examination of an ablated renal tumour has not yet been studied, compromising the correct and scientific evaluation of this new technology.
Primary Objectives:
- To determine the efficacy of IRE ablation of renal masses , measured by histopathologic examination of the targeted tumour.
- To determine the safety of IRE ablation of renal masses, by evaluating device and procedural adverse events.
Secondary Objectives:
- To evaluate the efficacy of MRI in the imaging of ablation success, extend of the ablation zone, one and four weeks post IRE ablation.
- To evaluate the efficacy of CEUS in the imaging of ablation success, extend of the ablation zone, one and four weeks post IRE ablation.
Population:
10 patients, age ≥ 18 years, presenting with a solid enhancing mass, who are candidates for radical nephrectomy.
Intervention:
Eligible patients will receive IRE ablation of their renal mass 4 weeks prior to radical nephrectomy. Follow-up at one and four weeks post IRE will be performed using MRI and CEUS imaging. After radical nephrectomy histopathological examination will be performed to evaluate IRE ablation success.
Study Overview
Detailed Description
Rationale:
The past decades have shown an increase in the incidence of small renal masses (SRM). At the moment laparoscopic partial nephrectomy is the 'golden standard' in treatment of SRMs. Thermal ablation techniques are indicated in patients who are poor surgical candidates or who have a predisposition to develop multiple tumours. Recent studies have shown thermal ablation techniques to have similar long-term oncologic results. Downsides to thermal ablation are the possible damage to vital structures in the vicinity of the ablation zone, e.g. collecting system or intestine, and unpredictable results due to difficulty in monitoring the ablation zone and 'thermal sink'.
Electroporation or electropermeabilisation is a novel technique with the potential to overcome the main disadvantages of thermal ablation. It utilizes electric pulses, traveling between two or more electrodes, to create 'nanopores' in the cell membrane. If the applied current reaches a certain threshold these 'nanopores' become permanent resulting in cell death. The use of electric current means that IRE is not susceptible to 'thermal sink' leading to consistent ablation results. IRE ablation targets the cell membrane, sparing tissue architecture and minimizing damage to blood vessels, nerves and the renal collecting system.
The first in human studies have proven the safety of IRE for the ablation of small renal masses. However the efficacy of IRE through histopathological examination of an ablated renal tumour has not yet been studied, compromising the correct and scientific evaluation of a new technology. This is the primary objective of this research project.
Objectives:
Primary Objectives:
- To determine the efficacy of IRE ablation of renal masses , measured by histopathologic examination of the targeted tumour.
- To determine the safety of IRE ablation of renal masses, by evaluating device and procedural adverse events.
Secondary Objectives:
- To evaluate the efficacy of MRI in the imaging of ablation success, extend of the ablation zone, one and four weeks post IRE ablation.
- To evaluate the efficacy of CEUS in the imaging of ablation success, extend of the ablation zone, one and four weeks post IRE ablation.
Study design:
This is a prospective, human, in-vivo pilot study. Study population: 10 patients, age ≥ 18 years, presented with a solid enhancing RM , who are candidates for radical nephrectomy.
Intervention:
Patients will receive IRE ablation of the RM, performed under general anaesthesia, 4 weeks before radical nephrectomy. Follow-up at one and four weeks post IRE will be performed using MRI and CEUS imaging. After radical nephrectomy histopathological examination will be performed to evaluate IRE ablation success.
Main study parameters/endpoints:
Primary endpoints:
- The efficacy of IRE ablation of renal masses , measured by histopathologic examination of the targeted tumour by an experienced genitourinary pathologist. Using immunehistochemical staining to evaluate cell viability.
- The safety of IRE ablation of renal masses, by evaluating device and procedural adverse events using CTCAE v4.0.
Secondary endpoints:
- The efficacy of MRI in the imaging of ablation success, extend of the ablation zone, one and four weeks post IRE ablation. By comparing MRI imaging to the histopathological examination results of the resected material.
- The efficacy of CEUS in the imaging of ablation success, extend of the ablation zone, one and four weeks post IRE ablation. By comparing CEUS imaging to the histopathological examination results of the resected material.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness:
There are no benefits for patients that participate in this study. Study participants will be exposed to additional risk when compared to standard treatment. They will have to undergo an additional procedure under general anaesthesia with muscle relaxation. The exposure to ionizing radiation during the procedure has been estimated at 32 mSv. Patients have to be informed about the risks of procedural complications. Information on the efficacy of IRE, proven histopathologically, is a vital step in order to progress to long term follow-up studies without tumour excision. So far no study has investigated the efficacy of IRE for the ablation of renal tumours in this manner.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Prof. M. Pilar Laguna Pes, M.D. Ph.D.
- Phone Number: +31(0)20-5668637
- Email: m.p.lagunapes@amc.nl
Study Contact Backup
- Name: Peter GK Wagstaff, M.D.
- Phone Number: +31(0)205666493
- Email: p.g.wagstaff@amc.nl
Study Locations
-
-
-
Amsterdam, Netherlands
- Recruiting
- Dept. Urology, Academic Medical Center, Amsterdam
-
Contact:
- Prof. M. Pilar Laguna Pes, M.D. Ph.D.
- Phone Number: +31(0)20-5668637
- Email: m.p.lagunapes@amc.nl
-
Contact:
- Peter GK Wagstaff, M.D.
- Phone Number: +31(0)205666493
- Email: p.g.wagstaff@amc.nl
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age ≥ 18 years
- Solid, enhancing mass on cross sectional imaging
- Scheduled for a radical nephrectomy, open or laparoscopic.
- Signed informed consent
Exclusion Criteria:
- Irreversible bleeding disorders
- Inability/unwillingness to interrupt anticoagulation therapy
- Previous cryoablation, RFA or partial nephrectomy in affected kidney
- Anaesthesia Surgical Assignment (ASA), category ≤ IV
- ICD / pacemaker
- Severe cardiovascular disease in medical history
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Irreversible Electroporation
Percutaneous, CT guided, Irreversible Electroporation of renal mass
|
Percutaneous, CT guided, ablation of renal mass
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The efficacy of IRE ablation of renal masses , measured by histopathologic examination of the targeted tumour by an experienced genitourinary pathologist. Using immunehistochemical staining to evaluate cell viability.
Time Frame: 1 month
|
1 month
|
Number of device and procedural adverse events using CTCAE v4.0.
Time Frame: 1 month
|
1 month
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The efficacy of MRI in the imaging of ablation success
Time Frame: 1 month
|
The efficacy of MRI in the imaging of ablation success, extend of the ablation zone, one and four weeks post IRE ablation.
By comparing MRI imaging to the histopathological examination results of the resected material.
|
1 month
|
The efficacy of CEUS in the imaging of ablation success
Time Frame: 1 month
|
The efficacy of CEUS in the imaging of ablation success, extend of the ablation zone, one and four weeks post IRE ablation.
By comparing CEUS imaging to the histopathological examination results of the resected material.
|
1 month
|
Collaborators and Investigators
Investigators
- Principal Investigator: Prof. M. Pilar Laguna Pes, M.D. Ph.D., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
- Study Chair: Prof. Jean J de la Rosette, M.D. Ph.D., Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL 44785.018.13
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Kidney Cancer
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnKidney/Urinary Cancer
-
PfizerCompletedKidney Cancer | Kidney Neoplasms | Renal Cell Carcinoma | Renal Cancer | Renal Cell Cancer | Cancer of the Kidney | Cancer of KidneyFinland
-
Tianjin Medical University Second HospitalRecruiting
-
Tianjin Medical University Second HospitalRecruiting
-
Cedars-Sinai Medical CenterRecruitingProstate Cancer Stage II | Prostate Cancer Stage I | Bladder Cancer Stage II | Kidney Cancer Stage IUnited States
-
Dana-Farber Cancer InstituteCompletedKidney Cancer | Prostate Cancer | Genitourinary CancerUnited States
-
Intuitive SurgicalCompleted
-
University of Texas Southwestern Medical CenterCompletedKidney Cancer | Kidney Cancer Metastatic | Kidney Cancer, Stage IVUnited States
-
Yale UniversityCompleted
-
Stanford UniversityNational Cancer Institute (NCI)WithdrawnProstate Cancer | Bladder Cancer | Kidney Tumor
Clinical Trials on Nano Knife
-
RenJi HospitalRuijin Hospital; Shanghai General Hospital, Shanghai Jiao Tong University School...UnknownPancreatic Cancer | Locally Advanced Pancreatic CanerChina
-
Aalborg University HospitalUppsala University HospitalCompletedPancreatic CancerDenmark
-
Karolinska InstitutetWithdrawnImmune Response | Hepatocellular CarcinomaSweden
-
Xijing Hospital of Digestive DiseasesCompletedStomach Cancer | Esophageal Cancer | Esophageal Dysplasia | Stomach DysplasiaChina
-
Fu Xing Hospital, Capital Medical UniversityRecruitingIntrauterine AdhesionChina
-
The Cooper Health SystemWithdrawnMetastatic Cancer | Brain MetastasesUnited States
-
Thammasat UniversityCompleted
-
University of TriesteCompleted
-
Zhujiang HospitalNanfang Hospital of Southern Medical UniversityUnknown
-
Stanford UniversityNu Skin EnterprisesCompletedSkin DiseasesUnited States